Vertex Pharmaceuticals
VRTX
NZ$785.95
Share price
1.64%
Change (1 day)
-6.88%
Change (1 year)
Categories
Vertex Pharmaceuticals (VRTX) - Total debt
Total debt on the balance sheet as of March 2025 : NZ$2.76 Billion
According to Vertex Pharmaceuticals's latest financial reports the company's total debt is NZ$2.76 Billion. A company’s total debt is the sum of all current and non-current debts.
Vertex Pharmaceuticals - Total debt on balance sheet (from 1996 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | NZ$3.10 B | 142.67% |
| 2023-12-31 | NZ$1.27 B | -9.79% |
| 2022-12-31 | NZ$1.41 B | 0.05% |
| 2021-12-31 | NZ$1.41 B | 9.66% |
| 2020-12-31 | NZ$1.29 B | 31.46% |
| 2019-12-31 | NZ$0.98 B | 12.3% |
| 2018-12-31 | NZ$0.87 B | 2.45% |
| 2017-12-31 | NZ$0.85 B | -29.65% |
| 2016-12-31 | NZ$1.21 B | 0.54% |
| 2015-12-31 | NZ$1.20 B | 14.66% |
| 2014-12-31 | NZ$1.05 B | 70.79% |
| 2013-12-31 | NZ$0.61 B | -27.23% |
| 2012-12-31 | NZ$0.84 B | 45.01% |
| 2011-12-31 | NZ$0.58 B | -16.07% |
| 2010-12-31 | NZ$0.69 B | 228.63% |
| 2009-12-31 | NZ$0.21 B | -57.25% |
| 2008-12-31 | NZ$0.49 B | 1797.72% |
| 2007-12-31 | NZ$26.1 M | -85.14% |
| 2006-12-31 | NZ$0.17 B | -33.33% |
| 2005-12-31 | NZ$0.26 B | -43.88% |
| 2004-12-31 | NZ$0.46 B | -8.48% |
| 2003-12-31 | NZ$0.51 B | -18.19% |
| 2002-12-31 | NZ$0.62 B | -20.53% |
| 2001-12-31 | NZ$0.78 B | -3.51% |
| 2000-12-31 | NZ$0.81 B | 5953.27% |
| 1999-12-31 | NZ$13.5 M | -27.36% |
| 1998-12-31 | NZ$18.59 M | 28.47% |
| 1997-12-31 | NZ$14.47 M | 20.32% |
| 1996-12-31 | NZ$12.03 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | NZ$41.86 B | 1,413.07% | 🇺🇸 USA |
 AbbVie ABBV | NZ$117.26 B | 4,138.01% | 🇺🇸 USA |
 Merck MRK | NZ$58.46 B | 2,012.91% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$85.97 B | 3,007.09% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$87.67 B | 3,068.52% | 🇺🇸 USA |
 Enanta Pharmaceuticals
ENTA | NZ$98.54 M | -96.44% | 🇺🇸 USA |